ES2010131A6 - Metodo de escrutinio para inhibidores y activadores de proteinas. - Google Patents

Metodo de escrutinio para inhibidores y activadores de proteinas.

Info

Publication number
ES2010131A6
ES2010131A6 ES8900455A ES8900455A ES2010131A6 ES 2010131 A6 ES2010131 A6 ES 2010131A6 ES 8900455 A ES8900455 A ES 8900455A ES 8900455 A ES8900455 A ES 8900455A ES 2010131 A6 ES2010131 A6 ES 2010131A6
Authority
ES
Spain
Prior art keywords
protein
activators
screening
identified
protein inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8900455A
Other languages
English (en)
Inventor
Gerard M Housey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenics Pharmaceuticals Inc
Original Assignee
Progenics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22550430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2010131(A6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Progenics Pharmaceuticals Inc filed Critical Progenics Pharmaceuticals Inc
Publication of ES2010131A6 publication Critical patent/ES2010131A6/es
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LOS INHIBIDORES Y ACTIVADORES DE UNA PROTEINA, CUYA PRODUCCION AFECTA A UNA CARACTERISTICA FENOTIPICA DE LA CELULA, ESPECIALMENTE A UNA CARACTERISTICA MORFOLOGICA O DEL CULTIVO, SON IDENTIFICADOS POR SU EFECTO MAS PRONUNCIADO SOBRE LAS CELULAS QUE PRODUCEN NIVELES MAS ALTOS DE LA PROTEINA, USUALMENTE NO NATURALES, QUE EN LAS CELULAS QUE PRODUCEN UNA PEQUEÑA CANTIDAD DE LA PROTEINA O NINGUNA. EN ENSAYO SERIA PREFERIBLE UNO EN QUE EL EFECTO ES OBSERVABLE A SIMPLE VISTA. POR ESTE METODO, EL TAMOXIFEN ES IDENTIFICADO COMO UN INHIBIDOR DE LA ACTIVIDAD DE LA PKC EN EL CULTIVO DE CELULAS.
ES8900455A 1988-02-10 1989-02-08 Metodo de escrutinio para inhibidores y activadores de proteinas. Expired ES2010131A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/154,206 US4980281A (en) 1988-02-10 1988-02-10 Method of screening for protein inhibitors and activators

Publications (1)

Publication Number Publication Date
ES2010131A6 true ES2010131A6 (es) 1989-10-16

Family

ID=22550430

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8900455A Expired ES2010131A6 (es) 1988-02-10 1989-02-08 Metodo de escrutinio para inhibidores y activadores de proteinas.

Country Status (18)

Country Link
US (1) US4980281A (es)
EP (1) EP0403506B1 (es)
JP (1) JPH03503598A (es)
AT (1) ATE140267T1 (es)
AU (1) AU612948B2 (es)
BG (1) BG60325B2 (es)
CA (1) CA1334927C (es)
DE (1) DE68926816T2 (es)
DK (2) DK189590A (es)
ES (1) ES2010131A6 (es)
FI (1) FI102618B (es)
HU (1) HU208555B (es)
IE (1) IE77332B1 (es)
IL (1) IL89227A (es)
MX (1) MX165993B (es)
NO (2) NO313103B1 (es)
RO (1) RO118452B1 (es)
WO (1) WO1989007654A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5322801A (en) * 1990-04-19 1994-06-21 The General Hospital Corporation Protein partner screening assays and uses thereof
WO1991016429A1 (en) * 1990-04-19 1991-10-31 The General Hospital Corporation Protein partner screening assays and uses thereof
US6080540A (en) * 1990-04-20 2000-06-27 Cold Spring Harbor Laboratory Cloning of mammalian genes in microbial organisms and methods for pharmacological screening
FI931268A7 (fi) * 1990-09-24 1993-04-21 Massachusetts Gen Hospital Seulontamenetelmiä
US5707810A (en) * 1991-03-11 1998-01-13 Creative Biomolecules, Inc. Method of diagnosing renal tissue damage or disease
US5650276A (en) * 1991-03-11 1997-07-22 Creative Biomolecules, Inc. Morphogenic protein screening method
ATE469228T1 (de) * 1991-04-19 2010-06-15 Univ Washington Dns, die für phosphodiesterasen von säugetieren kodiert
US5747341A (en) * 1991-06-24 1998-05-05 Pacific Biomedical Research, Inc. Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
ATE215605T1 (de) * 1991-06-24 2002-04-15 Pacific Biomedical Res Inc In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
US5821121A (en) * 1991-06-24 1998-10-13 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
WO1993002209A1 (en) * 1991-07-22 1993-02-04 The Regents Of The University Of California Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex
AU696364B2 (en) * 1991-08-30 1998-09-10 Creative Biomolecules, Inc. Morphogenic protein screening method II
ATE197611T1 (de) * 1991-08-30 2000-12-15 Creative Biomolecules Inc Screeningverfahren von morphogenischen proteinen
GB9216654D0 (en) * 1992-08-05 1992-09-16 Imp Cancer Res Tech Transformed cells and assays using them
US6048850A (en) * 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US5837479A (en) * 1992-09-22 1998-11-17 Young; Donald A. Screening assays for inhibitors of mammalian prostaglandin H synthase-2
DE4306547C2 (de) * 1993-03-03 1996-07-11 Gsf Forschungszentrum Umwelt In-vitro-Test zur Detektion von Proteinkinase C Inhibitoren
AU677834B2 (en) * 1993-04-07 1997-05-08 Cancer Research Ventures Limited Methods for screening of substances for therapeutic activityand yeast for use therein
US5776685A (en) * 1993-07-19 1998-07-07 Joslin Diabetes Center Protein kinase C assay
JPH09510104A (ja) * 1994-03-10 1997-10-14 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 形質転換の進行の誘導性阻害剤を同定する方法
EP0773952B1 (en) * 1994-07-20 2003-11-12 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US6399296B1 (en) * 1994-07-20 2002-06-04 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5597697A (en) * 1994-09-30 1997-01-28 Diamond; Paul Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases
KR100402836B1 (ko) * 1995-05-11 2004-02-19 주식회사 엘지생명과학 단백질간의상호작용을조절하는물질의새로운탐색시스템
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6153380A (en) 1996-01-23 2000-11-28 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
AU724107B2 (en) * 1997-01-31 2000-09-14 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin E
WO1999017798A1 (en) 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
JP2001507581A (ja) 1997-11-07 2001-06-12 アイコニックス・ファーマシューティカルズ・インコーポレーテッド 代用遺伝学的標的解析法
JP2001522598A (ja) 1997-11-10 2001-11-20 ザ ジュネラル ホスピタル コーポレーション タンパク質相互作用を記録するための検出システムおよび機能的関係
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6518035B1 (en) 1998-06-02 2003-02-11 Rosetta Inpharmatics, Inc. Targeted methods of drug screening using co-culture methods
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US6589738B1 (en) 1999-11-09 2003-07-08 Elitra Pharmaceuticals, Inc. Genes essential for microbial proliferation and antisense thereto
DE60143192D1 (de) 2000-02-08 2010-11-18 Sangamo Biosciences Inc Zellen zur entdeckung von medikamenten
AU2001289284A1 (en) * 2000-04-04 2001-10-15 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
CA2408743A1 (en) * 2000-05-25 2001-11-29 Curagen Corporation Method of detecting inflammatory lung disorders
US20030124524A1 (en) * 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20030170694A1 (en) * 2001-12-21 2003-09-11 Daniel Wall Stabilized nucleic acids in gene and drug discovery and methods of use
US20040126837A1 (en) * 2002-05-23 2004-07-01 Matthew Baker Pseudo-tissues and uses thereof
AU2002325299A1 (en) 2002-07-04 2004-02-16 Nalan Utku Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
EP1534856A2 (en) * 2002-09-02 2005-06-01 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of thyroid hormone binding protein for neurodegenerative diseases
AU2003301348A1 (en) * 2002-10-18 2004-05-04 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
DE602004015064D1 (de) 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
US20050266409A1 (en) * 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
KR20050106483A (ko) * 2003-03-04 2005-11-09 와이어쓰 천식 또는 그 밖의 알러지성 또는 염증성 질환을 진단 및치료하기 위한 조성물 및 방법
WO2004094647A2 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
WO2005001092A2 (en) * 2003-05-20 2005-01-06 Wyeth Compositions and methods for diagnosing and treating cancers
US8071652B2 (en) * 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
US20050164167A1 (en) * 2004-01-28 2005-07-28 Buscher Benjamin A. Method of discovery and development of broad-spectrum antiviral drugs
AU2005247943A1 (en) 2004-05-23 2005-12-08 Gerard M. Housey Theramutein modulators
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
CA2631182C (en) * 2005-11-23 2019-08-06 Hmi, Inc. Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
EP1878744A1 (en) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
AU2007353317B2 (en) * 2006-11-15 2012-09-06 Eli Lilly And Company Methods and compositions for treating influenza

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4480038A (en) * 1982-04-30 1984-10-30 E. I. Dupont De Nemours And Company Density separation of protein overproducing bacteria
US4532204A (en) * 1982-07-19 1985-07-30 Massachusetts Institute Of Technology Mutation assays involving blood cells that metabolize toxic substances
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators

Also Published As

Publication number Publication date
NO903494D0 (no) 1990-08-08
BG60325B2 (bg) 1994-05-27
FI903918A0 (fi) 1990-08-08
NO20021142D0 (no) 2002-03-07
DK189590D0 (da) 1990-08-09
JPH03503598A (ja) 1991-08-15
MX165993B (es) 1992-12-15
FI102618B1 (fi) 1999-01-15
IE890398L (en) 1989-08-10
RO118452B1 (ro) 2003-05-30
IL89227A (en) 1995-05-26
EP0403506A4 (en) 1991-07-24
NO903494L (no) 1990-10-01
IE77332B1 (en) 1997-12-02
DE68926816T2 (de) 1997-01-09
NO20021142L (no) 1990-10-01
CA1334927C (en) 1995-03-28
DK200100720A (da) 2001-05-08
WO1989007654A1 (en) 1989-08-24
AU3184089A (en) 1989-09-06
DE68926816D1 (de) 1996-08-14
ATE140267T1 (de) 1996-07-15
IL89227A0 (en) 1989-09-10
AU612948B2 (en) 1991-07-18
HU208555B (en) 1993-11-29
HUT55447A (en) 1991-05-28
FI102618B (fi) 1999-01-15
EP0403506A1 (en) 1990-12-27
NO313103B1 (no) 2002-08-12
DK189590A (da) 1990-10-02
US4980281A (en) 1990-12-25
EP0403506B1 (en) 1996-07-10

Similar Documents

Publication Publication Date Title
IL89227A0 (en) Method of screening of protein inhibitors and activators
MXPA99007026A (es) Metodo para proliferacion y diferenciacion de celulas hematopoieticas y mesenquimatosas.
AU2126688A (en) Serum free media for the growth of insect cells and expression of products thereby
DK0534955T3 (da) Fremgangsmåde til fremstilling af en zeaxanthinholdig sammensætning under anvendelse af en mikroorganisme af arten Flavobacterium multivorum.
ATE250664T1 (de) In vitro reifen von oozyten mit inhibitin/activin kombinationen
NO20006096D0 (no) Medium for dyrking av dyreceller og fremgangsmåte for fremstilling av protein ved anvendelse av det samme
CA2058930A1 (en) Media for cell growth and method for making them
Platt et al. Phytoplankton nutrients and flushing of inlets on the coast of Nova Scotia
PL327200A1 (en) Endothelium cells proliferation inhibitor and methods of using same
EP0758681A3 (en) Inhibition of the transformation of the cells with increased purine metabolic enzyme activity
ES8504245A1 (es) Procedimiento para la obtencion de sarcosin-oxidasa
AU2001226929A1 (en) Assessment method
ES2060202T3 (es) Composicion detergente enzimatica liquida.
DE69634363D1 (de) Vorläufer von normalen neuralen epithelzellen
ES2189971T3 (es) Aparato para cultivar microorganismos.
BR9106365A (pt) Processo para a preparacao de enzimas lignoliticas por meio de phanerochaete chrysosporium
Ruiz Rejón et al. Genetic variability in Muscari comosum L.(Liliaceae) IV Geographical distribution and adaptive role of the polymorphic variants of chromosome 2
GB1345429A (en) Device for stdying bacteria
AU6295390A (en) Cell culture methods for producing activated protein c
NZ310563A (en) DNA encoding a porcine complement inhibitor
Butler Effects of autoinhibition on hyphal growth in Coprinus disseminatus
AU574048B2 (en) Hydrogen uptake gene cosmid and process of constructing same
AU7221596A (en) Screening assay for k+ channel agonists
DE69014723D1 (de) Zellzüchtungsverfahren.
KR910012253A (ko) 폴리-3-히드록시부티르산의 생합성 방법

Legal Events

Date Code Title Description
FD2A Announcement of lapse in spain

Effective date: 20180802